Following recent struggles in the industry, the leading annual 8th Oncolytic Virotherapy Summit returns to Boston, MA in December (12-14), as the industry’s definitive, and most comprehensive forum. Bringing you 29+ world-class speakers, 10+ hours of networking, 2-panel discussions, 1 pre-conference focus day & more. This event will be showcasing brand-new pivotal data to ensure a pathway of success for regulatory approval of OV drugs.

3 days of carefully curated sessions will gather 100+ OV trailblazers across sessions spanning Early Discovery, Translation, Clinical Development, Chemistry, Manufacturing & Controls (CMC), and Regulations to overcome the industry’s largest and critical bottlenecks. Here is just a snapshot of our world-class speaker line-up who will be showcasing their expertise and critical updates:

• Richard Dambra, Scientist, Viral Platforms, Boehringer Ingelheim
• Francesca Barone, CSO, Candel Therapeutics
• Michael Franti, Director, Viral Platform Drug Metabolism & Pharmacokinetics, Boehringer Ingelheim
• Paul Hallenbeck, Chief Scientific Officer, Seneca Therapeutics
• Talia Biran, President Clinical Development Operations, Oncolys

This year’s edition brings highly promising content such as the exclusive Innovation Showcase, a whole day dedicated to Clinical Design & Manufacturing Strategies and a must-attend Investor Panel from experts in Biopharma.

As the only and longest established end-to-end OV-focused conference, this is a crucial date in the industry calendar you cannot afford to miss.

To know more visit: https://ter.li/1ag3m6